OSI Pharmaceuticals

February 7, 2012

Monoclonal Antibody Companies Command Premiums

July 11, 2010 By MD Becker Partners Leave a Comment

Monoclonal antibody image from MD Becker Partners

Monoclonal antibodies, which have been approved for immunological, anti-infective, ophthalmic, cancer and other categories, represent one of the most successful therapeutic drug classes. Ten monoclonal antibodies have been approved for cancer therapy alone, including three blockbuster products sold by the Roche Group (RHHBY) – Avastin® [bevacizumab], Rituxan® [rituximab], and Herceptin® [trastuzumab] that collectively represented nearly [...]

Filed Under: Articles Tagged With: Abbott, Abgenix, ABT, adalimumab, Agensys, Alexion Pharmaceuticals, ALXN, Astellas Pharma, AstraZeneca, Avastin, Bayer Schering Pharma AG, BAYRY.PK, bevacizumab, biosimilars, BMY, Bristol-Myers Squibb, Cambridge Antibody Tech, CEPH, Cephalon, Ception Therapeutics, cetuximab, Domantis, Eli Lilly & Co, Erbitux, erlotinib, Facet Biotech, FDA, GEN.CO, Genmab A/S, GENZ, Genzyme, Herceptin, HGSI, Human Genome Sciences, Humira, ImClone Systems, IMGN, IMMU, ImmunoGen, Immunomedics, Inc., infliximab, KaloBios Pharmaceuticals, LLY, mAbs, MacroGenics, MedImmune, Micromet, MITI, monoclonal antibodies, MORG.DE, Morphosys AG, Morphotek, NASDAQ Biotechnology Index, NBI, NeuTec Pharma plc, OncoMed Pharmaceuticals, OSI Pharmaceuticals, PFE, Pfizer, Regeneron, REGN, Remicade, RHHBY, Rinat Neuroscience Corp, Rituxan, rituximab, roche, sanofi-aventis Group, Seattle Genetics, SGEN, SNY, Tarceva, trastuzumab, Tufts Center for the Study of Drug Development, XOMA

For Biotechnology in 2010, it’s Déjà vu All over Again

March 7, 2010 By MD Becker Partners 2 Comments

Business Graph

“It’s déjà vu all over again” – Yogi Berra With Opening Day less than a month away, it seems only fitting to reference one of the most quoted personalities of our time to describe our analysis of the biotechnology sector in 2010. In this article, we review our favorable outlook for the industry, draw comparisons [...]

Filed Under: Articles Tagged With: Adventrix Pharmaceuticals, Alfrezza, Alkermes, ALKS, AMAG, AMAG Pharmaceuticals, AMLN, Amylin, ANX, Astellas Pharma, biotechnology, Cell Therapeutics, CEPH, Cephalon, Ception, CTIC, DCTH, DelCath Systems, Dendreon, DNDN, FDA approvals, InterMune, ISIS, Isis Pharmaceuticals, ITMN, Life Sciences Industry Outlook, MannKind Corporation, MDVN, Medivation, MNKD, NASDAQ Biotech Index, Novelos, NVLT, OSI Pharmaceuticals, OSIP, Provenge, Xenoport, XNPT